IPO Details

About Company

Molbio Diagnostics Ltd., incorporated in 2008, is a pioneering Indian company specializing in molecular diagnostics, particularly in the field of infectious diseases. The company is known for its flagship product, Truenat, a point-of-care testing platform that provides rapid and accurate results for various diseases, including tuberculosis and COVID-19. As a part of the growing healthcare sector, Molbio aims to enhance diagnostic capabilities across India and beyond. The company has established significant manufacturing capacities with state-of-the-art facilities in Goa, which enable it to produce high-quality diagnostic kits. Molbio's geographic presence extends throughout India, with a robust distribution network that includes hospitals, clinics, and laboratories, ensuring accessibility to its products across urban and rural areas. In terms of financials, Molbio reported a total income of INR 150 crores and a net profit of INR 30 crores for the latest fiscal year, with an EBITDA margin of 25%. The company boasts a Return on Capital Employed (ROCE) of 18% and a Return on Equity (ROE) of 15%, while maintaining a healthy Debt-Equity ratio of 0.5. The objectives of the IPO include funding expansion plans, enhancing manufacturing capabilities, and reducing debt. Post-issue, the market capitalization is expected to reach approximately INR 1,200 crores, with an Earnings Per Share (EPS) projected at INR 10 and a Price-to-Earnings (P/E) ratio of 25. Investor sentiment appears positive, driven by the growing demand for reliable diagnostic solutions and the company's innovative approach to healthcare.